• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Analysts: Japan approves 12 new procedures for Intuitive Surgical’s da Vinci

Analysts: Japan approves 12 new procedures for Intuitive Surgical’s da Vinci

January 18, 2018 By Brad Perriello

Intuitive SurgicalIntuitive Surgical (NSDQ:ISRG) recently won approval for an additional 12 procedures in Japan using its da Vinci robot-assisted surgery devices, according to analysts at Leerink Partners.

The approvals could represent an additional 200,000 cases in Japan, up from 30,000, Leerink analysts Richard Newitter and Jaime Morgan wrote this morning in a note to investors, citing talks with management, company reports and Leerink Partners estimates.

Previously only cleared for prostatectomy and nephrectomy in Japan, da Vinci is now approved for additional colorectal, gynecological and thoracic surgeries, plus gastrectomies, bladder cystectomies, esophagectomies and mitral valvuloplasty, The boost to worldwide procedure volumes could take time to realize, they cautioned, noting that Sunnyvale, Calif.-based Intuitive will have to invest in training and market development for each new area. And unlike the markets for prostatectomy and nephrectomy, which saw Intuitive convert from open to laparoscopic surgeries, many of the newer approvals are for procedures that are already being done laparoscopically, Newitter and Morgan wrote – making the adoption ramp slower for the new approvals.

Final reimbursement rates in Japan haven’t been set, they wrote, “so the economic incentive to convert procedures in these categories to robotics is still a bit of an unknown (recall that prostatectomy was reimbursed at a significant premium, which likely steepened that procedure’s adoption curve).”

Leerink maintained its “outperform” rating on ISRG shares but raised its price target to $475 from $390.

Here’s a look at the 14 procedures approved for Intuitive’s da Vinci in Japan, plus Leerink’s estimates on annual volumes:

Japan Procedures Est. # of Cases
Prostatectomy 20,000
Nephrectomy 10,000
Total Existing Opportunity 30,000
Colorectal
Lower Anterior Resection (Rectal) ~30,000 – 40,000
Gynecology
Malignant Hysterectomy ~10,000
Benign Hysterectomy ~50,000
Thoracic ~60,000
Lobectomy
Malignant Mediastinal
Benign Mediastinal
Gastrectomy ~50,000
Distal
Proximal
Other
Cystectomy (Bladder)
Esophagectomy
Mitral Valvuloplasty
Total Potential New Opportunity ~200,000

Filed Under: Regulatory/Compliance, Surgical Robotics, Wall Street Beat Tagged With: Intuitive Surgical

More recent news

  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • FDA posts alert for Edwards Lifesciences mitral valve delivery system after patient death
  • Former Medtronic RDN leader joins Teleflex
  • CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership
  • Stryker earns FDA clearance for new bone and soft tissue removal platform

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy